Abstract
Monocylic differentiation-inducing activity of steroidal side chain-lengthened 26,27-dialkyl analogs of 1α,25-dihydroxyvitamin D 3 was examined in human promyelocytic leukemia (HL-60) cells in serumsupplemented or serum-free culture. The order of in vitro potency for reducing nitroblue tetrazolium was 1α,25-dihydroxy-26,27-dimethylvilamin D 3, ≧ 1α,25-dihydroxyvitamin D 3 > 1α,25-dihydroxy-26,27-diethylvitamin D 3 ⪢ 1 α,25-dihydroxy-26,27-dipropylvitamin D 3 under serum-free culture conditions. Analysis by sucrose density-gradient centrifugation or polyethylene glycol precipitation technique showed that the potency order for differentiation-inducing activity correlated well with binding affinity of these analogs for vitamin D 3; receptor of HL-60 cells. Under serum-supplemented culture conditions, the lack of correlation between biologic activity and analog-binding affinity for receptor was caused by differences in binding affinity of these analogs for serum vitamin D-binding proteins. These results suggest that serum vitamin D-binding proteins apparently modulate monocytic differentiation of HL-60 cells by these analogs under serum-supplemented culture conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
